U.S. Prescription Sales Jumped 5.1 Percent In 2009, But Still At Low Levels, IMS Says
This article was originally published in The Pink Sheet Daily
The volume of add-on therapy starts, switches and refills grew nearly 2 percent, while the volume of new therapy starts declined slightly.
You may also be interested in...
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.
Elagolix could be the first oral drug approved for endometriosis that does not have severe side effects.